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ABSTRACT 
Objective: The aim of our study was to validate the accuracy of computational tools in drug discovery and molecular interaction studies by studying 
the inhibitory activity of various commercial drugs on DPP-4. 
Methods: In order to validate the accuracy of computational tools, 50 commercially available drugs were docked with DPP-4, a major target for type 
2 diabetes treatment. Studies were performed using Discovery studio 3.5. 
Results: The analysis showed that out of the fifty selected drugs, 33 drugs passed the Lipinski’s rule and commercially prescribed drugs namely 
Sulfonylurea, Pregabalin and Metaformin were found to have maximum interaction with the target. 
Conclusion: These major drugs which yielded the best results were found to be used in the treatment of diabetes which reconfirms the efficacy of 
these drugs, druggability of the target as well as the accuracy of the tool used. 
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Diabetes is a metabolic disorder characterized by hyperglycemia 
[Elevated blood glucose level] which results from insufficient insulin 
secretion, defects in insulin action or insulin resistance. Type 2 
diabetes represents 90-95% of diabetic cases and is the most 
prevalent form. It is characterized by either the failure in secretion 
of insulin or in action [1]. The critical factors that play a role in the 
disease include gender, age, lack of sleep, life style, diet and obesity. 
The disease can cause a series of complications associated with 
dysfunction and long-term damage to eyes, heart, kidneys, blood 
vessels and nerves [2].  
Dipeptidyl peptidase-4 (DPP-4) enzyme is a multifunctional type II 
transmembrane serine protease, which plays an important role in 
glucose metabolism [3, 4]. It is a complex enzyme that exists as an 
intrinsic membrane peptidase, responsible for the degradation of 
incretin such as glucagon-like peptide-1(GLP-1) which regulates the 
secretion of insulin from pancreas [5]. The action of GLP-1 is 
inactivated by the proteolytic activity of DPP-4. Thus by inhibiting 
DPP-4, the level of GLP-1 increases in blood and thereby releasing 
adequate insulin. Hence DPP-4 is a promising target for the 
treatment of type 2 diabetes [6]. Preclinical trials have also proved 
that DPP-4 inhibitors increase the level of GLP-1, which in turn 
increases insulin secretion and reduces glucagon secretion [7, 8].  
The rapid development of computational tools remarkably helps in 
closing the gap between in vitro and in silico methods. Application of 
these tools varies from genome sequencing to drug discovery. New 
medicines are developed based upon biological targets and their 
specific interactions such as hydrogen bonding, hydrophobic 
interactions, Van der Waals interactions and so on. Molecular 
docking is one such method among the various computational 
techniques which is used to predict how a drug interacts with the 
binding site of a target protein and returns the best hit through a 
series of scoring functions and statistics. Many docking programs 
are currently available; the present work proves the efficacy of the 
software, Discovery Studio 3.5 for in silico interaction studies. The 
results also highlight the best hit against DPP-4, among the 
commercial fifty drugs evaluated. 
The crystal structure of human apo dipeptidyl peptidase-4 (PDB ID: 
1PFQ) was retrieved from Protein Data Bank. The protein was found 
to be complexed with the ligand ‘N-acetyl-D-glucosamine’ with chain 
A and B. Chain A alone was used for protein preparation while chain 
B, ligand and water molecules were removed. Protein preparation 
module of Discovery Studio 3.5 was used to manipulate and 
interrogate protein structure which included correcting geometries, 
inserting missing loops, grafting loops, managing conformers and 
modify protonation of termini and ionizable side chains. This was 
followed by energy minimization of the structure to find out stable 
conformation using CharmM Force field. The receptor-ligand 
protocol of Discovery Studio and molecular dynamic simulation was 
used to predict the binding sites of the energy minimized protein 
structure.  
About fifty existing drugs for diabetes, cancer, HIV, cholesterol, 
Parkinson’s, heart diseases, hypertension, Alzheimer’s and diarrhea 
were randomly selected as ligands. The chemical structures of these 
compounds were retrieved from Pub Chem compound database [9]. 
These chemical compounds were filtered by Lipinski’s rule of five 
[10]in order to predict their biological and pharmacological 
properties as active drugs.  Selected drugs were successfully docked 
to the binding site of DPP-4 using CDOCKER protocol of Discovery 
Studio 3.5. The best hits were determined based on various scoring 
functions like CDOCKER energy, CDOCKER interaction energy, 
hydrogen bond interaction with the active site residues, binding 
energy, protein energy and complex energy.  
 
 
Fig. 1: Energy minimized structure of 
human apo dipeptidyl peptidase 4. 
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The retrieved structure of DPP-4 was prepared (fig. 1) and the active 
site was identified. Discovery studio was able to predict a binding 
site of the energy minimized structure with the amino acid residues 
GLN 314, SER 323, VAL 324, HIS 345, ILE 346, GLU 347, PHE 371, 
LYS 373, ILE 375 and PHE 387.  
Out of fifty, only thirty three drugs satisfied Lipinski’s rule. Drug 
likeness properties such as molecular weight, X log P, number of 
hydrogen bond donors and acceptors for the satisfied drugs are 
shown in table1. 
Drugs which showed good interaction with the active site were 
found to be sulfonylurea, Pregabalin and Metaformin. These three 
drugs formed hydrogen bond interaction with the amino acid 
residue HIS 345 in the active site of the target protein. CDOCKER 
energy of Sulfonylurea, Pregabalin and Metaformin is 28, 23 and 17 
respectively. Interaction of these drugs with the amino acids 
residues are shown in Fig. 2, 3 and 4 respectively. Binding energies 
of these drugs with the active site of DPP-4 were found to be -
46.9507, -78.8461 and -10.9464 Kcal/mol respectively and are 
shown in table 2. 
  
Table 1: Drug likeness of thirty three drugs 
S. No. Compound Name Compound ID Molecular weight (G/Mol) XLOGP3-AA H-Bond donor H-Bond Acceptor 
1 Aldara 57469 240.303 2.6 1 3 
2 Anastrozole 2187 293.366 2.1 0 4 
3 Calanolide-A 64972 370.439 3.8 1 5 
4 Carboplatin 10339178 371.254 - 2 6 
5 Cisplatin 83895 391.161 - 2 4 
6 Crizotinib 11626560 450.336 3.7 2 6 
7 Cycrimine 2911 287.439 3.9 1 2 
8 Dacogen 16886 228.205 -1.2 3 4 
9 Dasatinib 3062316 488.005 3.6 3 9 
10 Exemestane 60198 296.403 3.1 0 2 
11 Fluvastatin 446155 411.465 3.5 3 5 
12 Mevacor 53232 404.539 4.3 1 5 
13 Raltegravir 54671008 444.416 1.1 3 9 
14 Simvastatin 54454 418.566 4.7 1 5 
15 Zetia 150311 409.425 4 2 5 
16 Abacavir 441300 286.332 0.9 3 6 
17 Acenocoumarol 54676537 353.325 2.5 1 6 
18 Amoxicillin 33613 365.404 -2 4 7 
19 Ascorbic acid 54670067 176.124 -1.6 4 6 
20 Aspirin 2244 180.157 1.2 1 4 
21 Azacitidine 9444 244.204 -2.2 4 5 
22 Donepezil 3152 379.491 4.3 0 4 
23 Fluoxitine 3386 309.326 4 1 5 
24 Gabapentin 3446 171.236 -1.1 2 3 
25 Memantine 4054 179.301 3.3 1 1 
26 Torasimide 41781 348.42 2.7 3 5 
27 Metaformin 4091 129.163 -1.3 3 1 
28 Sulfonylurea 104818 182.158 -2.5 4 4 
29 Pregabalin 5486971 159.226 -1.6 3 2 
30 Benazepril 5362124 424.489 1.3 2 6 
31 Pravastatin 54687 424.527 1.6 4 7 
32 Amoldipine 2162 408.875 3 2 7 
33 Valsartan 60846 435.518 4.4 2 6 
 





H Bond H bond residues Binding Energy Protein Energy Complex Energy 
Sulfonylurea 
CID 104818 
28 27 2 HIS345 
LYS373 
-46.9507 -27986.8 -28055.7 
Pregabalin 
CID 5486971 
23 24 3 HIS345 
ILE346 
-78.8461 -27986.8 -28155.2 
Metaformin 
CID 4091 
17 20 1 HIS345 -10.9464 -27986.8 -28021.2 
 
 
Fig. 2: Interaction of Sulfonylurea with DPP4 
 
Fig. 3: Interaction of Pregabalin with DPP4 
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Fig. 4: Interaction of Metaformin with DPP4. 
 
Our study focused on the validation of docking software by 
testing the interaction of commercially available randomly 
selected drugs with DPP-4, a major target for diabetic treatment. 
Fifty drugs were randomly selected and the study confirmed that 
the widely used drugs for type 2 diabetes showed maximum 
interactions than the other selected drugs which are effective. 
For other diseases. Sulfonylurea, Pregabalin and Metaformin 
were the three drugs which showed good interaction with the 
target protein DPP-4 and also formed hydrogen bonds with the 
active site residue HIS 345, which confirms the residue as a 
major target for similar studies.  
Thereby we validated docking protocols through our comparative 
study on commercially available drugs. This study could also 
reconfirm the druggability of DPP-4 as a major diabetic target. Such 
computational studies will reduce time, cost and risk factors in the 
drug discovery process than the traditional methods. 
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